alm, I were +double wrong of you - and really feel good about it - course that it what AMRN and Vasepa 'is worth' easy ! --------------------------
What vent wrong in 2021 - well 'Just about everything' evaluating merely from SP being where it is.
That is not the whole story though.
Strong forces 'are sitting on this Stock' not to 'take of' - and the things that 'could have made AMRN 'Break out' in 2021 - like the Covid trial that fails, Covid still strong in Germany. China didn't yet approve as expected - reasons where we are.
We all know 'the value is there' in this drug - it just a matter of 'releasing the potential/selling it to the World - and long patient investors will be rewarded.